

ABSTRACT OF THE DISCLOSURE

5 The present invention is directed in part towards
methods of modulating the function of serine/threonine
protein kinases with quinazoline-based compounds. The
methods incorporate cells that express a serine/threonine
protein kinase, such as RAF. In addition, the invention
describes methods of preventing and treating
serine/threonine protein kinase-related abnormal conditions
in organisms with a compound identified by the invention.
10 Furthermore, the invention pertains to quinazoline
compounds and pharmaceutical compositions comprising these
compounds.